Market News AIOpen the app

Moleculin Biotech shared its third-quarter results and finished treating all patients in a key trial for Annamycin.

ResultsRead the original at SEC EDGAR
Good for MBRX

Moleculin completed treatment for all 90 patients in Part A, bringing its main AML trial closer to a data release. Heart-safety findings support the drug, but full results are still pending.

MBRX · Moleculin Biotech, Inc.

AI read · Good for MBRX

The AI's read

This brings Moleculin closer to choosing a dose for the next trial stage. A published review found no heart damage tied to Annamycin across five trials. But the full Part A results are still pending, so its benefit for AML patients has not yet been shown.

Get alerts for MBRX

Follow Moleculin Biotech, Inc. (MBRX) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for MBRX
Free on the App Store and Google Play, or on the web.